Clear Impact logo

Vermont Medicaid/CHIP (CCS-19)

CHL: Chlamydia Screening in Women - Age 16-20 (CCS-19)

Current Value

50.8%

2019

Definition

Line Bar

Notes on Methodology

  • The annual reported rate captures activity during the previous calendar year. 
  • This is a Healthcare Effectiveness & Data Information Set (HEDIS) administrative measure.
  • As of 2014, DVHA’s rates only include only Medicaid Primary beneficiaries in HEDIS administrative measures.
  • The target trend line is the 50th percentile national benchmark for Medicaid programs. 

Story Behind the Curve

This measure assesses the percentage of sexually active women 16-24 years of age who were screened for chlamydia during the measurement year. The Child Core Set asks states to report the rate for the subset of women ages 16-20 years of age (shown above).

Screening is essential because the majority of women who have the condition do not experience symptoms. The main objective of chlamydia screening is to prevent pelvic inflammatory disease (PID), infertility and ectopic pregnancy, all of which have very high rates of occurrence among women with untreated chlamydia infection.

Chlamydia trachomatis is the most common sexually transmitted disease (STD) in the U.S. Risk factors associated with becoming infected with chlamydia are the same risks for contracting other STD’s (e.g., multiple sex partners). Chlamydia is more prevalent among adolescent and young adult women.

Last updated:  February 2020

Clear Impact Suite is an easy-to-use, web-based software platform that helps your staff collaborate with external stakeholders and community partners by utilizing the combination of data collection, performance reporting, and program planning.

Scorecard Container Measure Action Actual Value Target Value Tag S A m/d/yy m/d/yyyy